Clinical genitourinary cancer最新文献

{"title":"Racial Differences in Survival for Locally Advanced Renal Cell Carcinoma.","authors":"Jean-Pierre Trey Kanumuambidi, Dmitry Tumin, Michael Blute","doi":"10.1016/j.clgc.2025.102327","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102327","url":null,"abstract":"<p><strong>Introduction: </strong>African Americans with renal cell carcinoma (RCC) often have more aggressive tumors and worse outcomes compared to other racial groups. The impact of race on survival in locally advanced RCC with tumor thrombus and metastatic RCC (mRCC) remains unclear. This study evaluates racial disparities in survival among RCC patients with tumor thrombus.</p><p><strong>Methods: </strong>This IRB-approved retrospective study analyzed 11,520 RCC patients aged 18 to 80 with tumor thrombus who underwent nephrectomy (2010-2015) using the National Cancer Database. Demographic factors (age, sex, race/ethnicity) and clinical variables (tumor stage, grade, thrombus level, surgery type, comorbidities) were included. Statistical analyses utilized Kaplan-Meier curves, Cox proportional hazards, and multinomial logistic regression, with significance set at P < .05.</p><p><strong>Results: </strong>African Americans (6% of patients) had a 22% higher overall mortality hazard (HR: 1.22, P < .001) and 24% higher hazard in metastatic RCC (HR: 1.24, P = .019) compared to non-Hispanic Whites (83%). Five-year survival rates for advanced thrombus levels (I-IV) were comparable between races. Overall mortality was 55%, rising to 82% in metastatic cases.</p><p><strong>Conclusion: </strong>Among patients with RCC and tumor thrombus, African American patients face 22% higher mortality hazard compared to non-Hispanic white patients. They often present with more locally advanced disease and mRCC. The mortality hazard for metastatic RCC is increased by 24% among African Americans compared to Caucasians. The results highlight the demographic impact of race and supports clinical consideration when managing African American patients.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102327"},"PeriodicalIF":0.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial Carcinoma: A Real-world Analysis From a Multicenter Study.","authors":"Makito Miyake, Nobutaka Nishimura, Yusuke Iemura, Motokiyo Yoshikawa, Kazumasa Torimoto, Atsushi Tomioka, Keichi Sakamoto, Yoshiaki Matsumura, Makito Naoi, Daiki Ichii, Kuniaki Inoue, Kosuke Narita, Nobuo Oyama, Mitsuru Tomizawa, Takuto Shimizu, Kenta Ohnishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto","doi":"10.1016/j.clgc.2025.102326","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102326","url":null,"abstract":"<p><strong>Objective: </strong>To provide real-world evidence regarding the association between the initial relative dose intensity (RDI) of enfortumab vedotin (iRDI-EV) during the first 2 to 3 cycles for locally advanced or metastatic urothelial carcinoma (la/mUC) and patient characteristics, including EV-Ineligible criTeriA (EVITA), tumor response, and survival.</p><p><strong>Methods: </strong>A multicenter database registered 83 patients with locally advanced or metastatic treated with late-line EV monotherapy between 2021 and 2023. The iRDI-EV was calculated based on the dose modification during the first 2 to 3 cycles. A dose of 1.25 mg/kg on days 1, 8, and 15 of a 28-day cycle was considered the standard full regimen. Patients were categorized into RDI-1 (lowest), RDI-2, RDI-3, and RDI-full (100% RDI) groups.</p><p><strong>Results: </strong>In total, 68 patients were available for iRDI-EV analysis and response evaluation. The overall median iRDI-EV was 87%, with 14, 13, 13, and 28 patients in the 4 groups exhibiting median iRDI-EV of 62%, 73%, 83%, and 100%, respectively. No clear association between the iRDI-EV and objective response was observed. The disease control rate was significantly higher in the RDI-full group (96%) than in the other groups. The patients in higher RDI groups (RDI-3/RDI-full) had longer progression-free survival than the lower RDI groups (RDI-1/RDI-2), with no difference in overall survival. A multiple linear regression analysis revealed higher iRDI-EV was a strong contributor to better response and longer survival. Of the 83 patients, 4 met ≥2 EVITA, exhibiting a higher risk of progression, whereas 79 had EVITA ≤1.</p><p><strong>Conclusions: </strong>Oncologists must continue to learn from real-world data on late-line EV monotherapy for combination therapy.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102326"},"PeriodicalIF":0.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geographic Distribution of Racial Differences in Renal Cell Carcinoma Mortality.","authors":"Xiaoxian Liu, Chengqian Shi, Bin Han, Jie Yang","doi":"10.1016/j.clgc.2025.102324","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102324","url":null,"abstract":"<p><strong>Objective: </strong>To examine the geographic variations in Renal cell carcinoma (RCC) -specific death disparities from competing causes among Hispanic, non-Hispanic White, non-Hispanic Black, and Asian/Pacific Islander RCC patients. RCC outcomes in specific racial/ethnic population warrants further research and it is unknown whether racial/ethnic differences in RCC survival vary geographically within the US.</p><p><strong>Methods: </strong>This retrospective cohort study was conducted to assess all RCC patients from 2014 to 2021. Data was extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The primary outcome was RCC-related mortality.</p><p><strong>Results: </strong>The study included 85,975 patients with RCC from 16 geographic areas within the SEER database. Kaplan-Meier analysis showed that Hispanic patients had the worst survival outcome (P < .001 by log rank test). In the multivariable competing-risks regression, Hispanics had a higher risk of cancer-specific mortality (hazard ratio [HR] 1.29, 95% CI, 1.20-1.38, P ˂ .001) compared with non-Hispanic Whites. The increase in the risk of RCC-related death with Hispanic race/ethnicity was consistent across all major subgroups stratified by the covariables. In stratified analyses of geographic regions, there were 3 areas in which Hispanics had worse RCC-specific survival (Los Angeles: HR 1.22, 95% CI, 1.06-1.41, P = .005; Greater California: HR 1.125, 95% CI, 1.15-1.37, P < .001; Atlanta, Georgia: HR 1.95, 95% CI, 1.32-2.88, P = .001).</p><p><strong>Conclusion: </strong>These results demonstrate that population-level variations in RCC survival among Hispanics and non-Hispanic Whites were associated with a small number of geographic regions. Targeted interventions in these regions may be conducive to alleviating RCC care differences at the national level.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102324"},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of the Continuous Care Model on Quality of Life, Sexual Satisfaction and Function in Bladder Cancer Patients Undergoing Tumor Resection Surgery: A Randomized Control Trial.","authors":"Fateme Rezaeeniya, Fateme Hasandoost, Amir Reza Abedi, Alireza Amanollahi, Soolmaz Moosavi","doi":"10.1016/j.clgc.2025.102321","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102321","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is a global health concern, and while surgery is vital, it often diminishes patient quality of life, notably sexual function. Existing self-care education is insufficient, necessitating a more holistic approach. The Continuous Care Model (CCM), which emphasizes patient empowerment, shows promise. This study investigates a CCM intervention that includes sexual health education to improve quality of life (QoL) and sexual satisfaction in bladder cancer patients.</p><p><strong>Methods: </strong>This randomized controlled trial enrolled 54 bladder cancer patients undergoing tumor resection surgery in Tehran, Iran (April-September 2024). Participants were randomly assigned to either a CCM intervention group (n = 26) and a control group (n = 28). QoL was assessed using the EORTC QLQ-C30; sexual function and satisfaction were measured using the Larson Sexual Satisfaction Questionnaire, IIEF, and FSFI at baseline and at 1 and 3 months postintervention.</p><p><strong>Results: </strong>The CCM group demonstrated significantly improved overall QoL (P < .001) and several subscales (physical, emotional, cognitive, fatigue) compared to controls. Sexual satisfaction also improved significantly in the CCM group (P < .001). Sexual function enhanced particularly for males (enhanced orgasm and sexual desire, P = .049, P = .020, respectively). No significant changes in female sexual function were observed, although past medical history (P = .019) and partner's job (P = .017) were significantly associated with female sexual function.</p><p><strong>Conclusions: </strong>The CCM intervention effectively enhanced QoL, sexual satisfaction, and sexual function particularly in males. Further research is needed to address the unique challenges impacting female patients' sexual function postbladder cancer surgery.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102321"},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell Carcinoma.","authors":"Masayuki Takahashi, Yuto Matsushita, Takahiro Kojima, Takahiro Osawa, Tomokazu Sazuka, Shingo Hatakeyama, Keisuke Goto, Kazuyuki Numakura, Kazutoshi Yamana, Shuya Kandori, Kazutoshi Fujita, Kosuke Ueda, Hajime Tanaka, Ryotaro Tomida, Toshifumi Kurahashi, Yukari Bando, Takahiro Kimura, Naotaka Nishiyama, Shimpei Yamashita, Hisanori Taniguchi, Keisuke Monji, Ryo Ishiyama, Yoshihide Kawasaki, Takuma Kato, Shuichi Tatarano, Kimihiko Masui, Eijiro Nakamura, Tomoyuki Kaneko, Makito Miyake, Goshi Kitano, Takanobu Motoshima, Yusuke Shiraishi, Satoru Kira, Takaya Murashima, Hiroaki Hara, Masafumi Matsumura, Hiroshi Kitamura, Hideaki Miyake, Junya Furukawa","doi":"10.1016/j.clgc.2025.102322","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102322","url":null,"abstract":"<p><strong>Introduction: </strong>Effectiveness and safety of second-line tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC) for whom first-line immuno-oncology (I-O) combination therapy was discontinued because of adverse events (AEs) remain to be determined.</p><p><strong>Patients and methods: </strong>Clinicopathological data were retrospectively collected from 34 institutions between August 2018 and January 2022 for 243 patients with mRCC who received second-line TKIs after first-line I-O combination therapy. Two patients who requested discontinuation of first-line I-O combination therapy were excluded. Oncological outcomes and safety were compared between patients who discontinued first-line I-O combination therapy because of progressive disease (Group PD) and AEs (Group AE). First- and second-line overall survival (OS) were defined as the time from the start of first- and second-line therapy to death, respectively. Propensity score matching was applied to adjust prognostic factors between the 2 groups.</p><p><strong>Results: </strong>There were 179 patients in Group PD and 62 patients in Group AE. Objective response rate and disease control rate were similar between the 2 groups. Progression-free survival (PFS), second-line OS, and first-line OS were significantly longer in Group AE than in Group PD (median 13.6 months vs. 8.5 months, P = 0.005; median not reached [NR] vs. 19.5 months, P = .005; median NR vs. 30.8 months, P = .012, respectively). After propensity score matching, PFS and second-line OS were still significantly longer and first-line OS tended to be longer in Group AE than in Group PD. There were no significant differences in the occurrence of AEs of any grade, including severe grades of 3 or greater, between the 2 groups.</p><p><strong>Conclusion: </strong>Second-line TKIs are safe and at least as effective in patients with mRCC who discontinued first-line I-O combination therapy because of AEs as they are in patients who discontinued because of PD.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102322"},"PeriodicalIF":0.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival in Responders and Nonresponders of Neoadjuvant and Induction Chemotherapy in Invasive Urothelial Carcinoma of the Urinary Bladder: A Clinical and Pathological Stage-Matched Analysis.","authors":"Daan J Reesink, Charlotte S Voskuilen, Ewoudt M W van de Garde, Kees Hendricksen, Simon Horenblas, Harm H E van Melick, Bas W G van Rhijn","doi":"10.1016/j.clgc.2025.102319","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102319","url":null,"abstract":"<p><strong>Introduction/background: </strong>A recent study reported that patients with residual urothelial carcinoma of the bladder subsequent to neoadjuvant/induction chemotherapy (NAIC) prior to RC exhibited inferior oncological outcomes in comparison to pathological stage-matched patients who underwent upfront RC. Our hypothesis is that this may be ascribed to variations in preoperative CT-stage rather than the impact of chemotherapy.</p><p><strong>Patients and methods: </strong>This retrospective multicentre study included 513 patients who underwent RC for cT2-4N0-3M0 disease between 2010 and 2017. Patients were categorized based on pathological outcomes: pathological complete response (pCR, (y)pT0N0), complete downstaging (pCD, (y)pT0/is/a/1N0) and residual muscle-invasive and/or node positive disease (rMIBC, (y)pT2-4N0 and/or (y)pN1-3).</p><p><strong>Results: </strong>Of the total cohort, 175 (34.1%) patients underwent NAIC+RC, while 338 (65.9%) underwent upfront RC. NAIC+RC patients exhibited lower age and CCI-scores, along with higher cT&N-stage (all P-values < .001). The mOS was 60.5 months for NAIC+RC and 49.4 months for upfront RC (P-value = .171). In patients with rMIBC, survival was inferior after NAIC+RC compared to upfront RC. However, the clinical stage distribution between NAIC+RC and upfront RC was imbalanced, with 3% versus 49% cT2N0 patients and 47% versus 9% cT4b and/or N+ patients, respectively. Following adjustments for cT & N-stage, age, and CCI-scores in multivariable Cox proportional-hazards analysis, worse OS was associated with upfront RC (HR 1.52, [95% CI, 1.11-2.10], P-value = .009).</p><p><strong>Conclusion: </strong>The observed inferior survival in cT2-4N0-3M0 patients with rMIBC after NAIC+RC compared to those undergoing upfront RC resulted from worse preoperative characteristics, including clinical stage. The representation of clinical disease stage should not be overlooked in survival analyses.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102319"},"PeriodicalIF":0.0,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC).","authors":"Dianne Bosch, Kim J M van der Velden, Tom Belleman, Welmoed K van Deen, André M Bergman, Maarten J van der Doelen, Alfons J M van den Eertwegh, Winald R Gerritsen, Reindert J A van Moorselaar, Diederik M Somford, Metin Tascilar, Hans M Westgeest, Carin A Uyl-de Groot, Peter F A Mulders, Malou C P Kuppen, Inge M van Oort","doi":"10.1016/j.clgc.2025.102317","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102317","url":null,"abstract":"<p><strong>Background: </strong>Androgen receptor targeted therapies (ART) play a major role in the treatment of metastatic castration-resistant prostate cancer (mCRPC). In recent years consensus has been reached that treatment with a second ART should be avoided due to low response rates. The aim of this study was to investigate if new scientific insights led to changes in clinical daily practice in the Netherlands.</p><p><strong>Methods: </strong>Patients included in the Dutch CAPRI-3 prostate cancer registry, currently encompassing 19 hospitals, and treated with at least 1 ART (ie, abiraterone or enzalutamide) were included. Patients were stratified based on start date of first ART (ART1) according to standard of care between 2016-2017, 2018-2019 and 2020-2021. Second ART (ART2) was defined as either direct (ART1>ART2) or at any given time (any ART2).</p><p><strong>Results: </strong>Between the first and last ART1 group, the prevalence of ART1>ART2 declined from 14.3% to 6.5% (P = .001) and the prevalence of any ART2 from 27.6% to 10.7% (P < .001). The decline was observed before recommendations were included in European guidelines. The use of other life-prolonging drugs (LPDs) after ART1 (ART1>LPD) increased. Patients who were selected for ART1>ART2 instead of ART1>LPD were older, less frequently treated with taxane-based chemotherapy for mHSPC and had a longer time to development of mCRPC.</p><p><strong>Conclusions: </strong>New scientific insights were incorporated into clinical daily practice, with a significant decline in in the prevalence of sequential ART treatment, even before recommendations were included in European guidelines.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102317"},"PeriodicalIF":0.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Neoadjuvant Immunotherapy and Chemotherapy for Muscle-Invasive Bladder Cancer in a National Registry.","authors":"Matthew N Klein, Oluwafolajimi Adesanya, Vince E Xu, Olivia Gordon, Ryan M Antar, Michael J Whalen","doi":"10.1016/j.clgc.2025.102316","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102316","url":null,"abstract":"<p><strong>Background: </strong>Based on remarkable success in the metastatic/locally advanced space, Neoadjuvant Immunotherapy (NIO) is a promising novel treatment option for Muscle-Invasive Bladder Cancer (MIBC). Here, we assess factors associated with NIO and describe survival outcomes following NIO use in MIBC patients.</p><p><strong>Methods: </strong>The NCDB was used to identify 5,823 qualifying patients with a diagnosis of urothelial bladder cancer, T2-4N0-3M0 clinical stage and who received NIO or NAC prior to radical cystectomy between 2006 and 2019. NAC and NIO patient groups with similar clinical and demographic characteristics were defined using a 1:1 propensity score matching method.</p><p><strong>Results: </strong>Mean age at diagnosis was significantly higher in NIO patients compared to NAC patients (70.22 ± 9.2 vs. 65.33 ± 9.1 years, P < .001). NAC administration correlated with an increased odds of pathologic complete response (pCR) compared to NIO in the unmatched (OR: 3.825, 95% CI: 1.972-7.417, P < .001) and matched (OR: 6.771, 95% CI: 2.624-17.473, P < .001) analyses. Finally, Cox proportional hazard model and Kaplan-Meier analysis revealed no difference in overall survival between NAC and NIO administration in the unmatched or matched analysis.</p><p><strong>Conclusion: </strong>In this study, older age, higher income and longer distance to facility were associated with the use of NIO compared to NAC. NIO administration was less effective at achieving pR and pCR compared to NAC. There was no observed difference in overall survival between patients that received NIO and those that received NAC. The ongoing phase III trials in this space should help to clarify the role of NIO.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102316"},"PeriodicalIF":0.0,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143569164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of a multidisciplinary tumour board (MTB) on treatment decision making for patients with renal cell carcinoma (RCC): 5-year data analysis","authors":"L. Brink, A. Ruiter, B. Lagerveld, N. Graafland, A. Bex, H. Beerlage, R.J.M. van Moorselaar, P. Zondervan","doi":"10.1016/j.clgc.2024.01.021","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.01.021","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"327 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139822790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study","authors":"Margaret Meagher, Kylie M. Morgan, Leah N. Deshler, Dhruv Puri, Kit Yuen, Aditya Bagrodia, Brent Rose, Tyler F Stewart, A. Salmasi","doi":"10.1016/j.clgc.2024.02.006","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.02.006","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"76 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139887499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}